Accolate (zafirlukast) has been approved for the preventative and chronic treatment of asthma in adults and children 12 years of age and older.
Accolate has been studied in more than 4,000 people worldwide. In clinical trials in patients with mild to moderate asthma, Accolate was shown to improve lung function and reduce daytime and nighttime asthma symptoms.
Accolate is the first leukotrine receptor antagonist, a new class of drugs, to receive FDA clearance. Accolate works by blocking the effect of leukotrines, natural substances in the body that can contribute to asthma symptoms.
More than 12 million Americans suffer from asthma, and worldwide more than 100 million people have this chronic lung disease.